A new paper in Frontiers in Science lays out a proposal rather than a tested treatment: that drugs modulating GPCR signaling, the cell-communication system that regulates hormones, metabolism, brain function and immune responses, could help delay multiple age-related diseases at the same time. The authors argue the potential lies in acting across many pathways in the body instead of targeting one receptor or one disease.
The reasoning starts with the observation that GPCR expression and signaling shift as people age, and those shifts are tied to several recognized hallmarks of aging. These include chronic low-level inflammation, reduced cellular energy production, impaired cell communication, difficulty maintaining healthy proteins, and the buildup of dysfunctional cells. Because GPCRs touch so many systems, their dysfunction is linked to conditions such as cardiovascular disease, cancer, metabolic disorders, and neurodegenerative diseases including Alzheimer's and Parkinson's.
The researchers say GPCRs are highly "druggable," meaning they can already be targeted by medicines, which they see as a practical starting point. They also suggest that the approach could eventually be personalized, with treatments guided by individual aging biomarkers, and could be combined with other longevity strategies such as metabolic therapies, regenerative medicine, and treatments that reduce chronic inflammation.
Co-author Dr Silke Dodel of AstraNexa, Deep Science, LLC, and Florida Atlantic University described personalization as a central promise, pointing to AI systems and human experts working together to identify drivers of processes at the level of GPCR networks. Co-author Prof Graham Ladds of the University of Cambridge said that combining network-level targeting with therapies that clear damaged aging cells, improve metabolism, or promote tissue repair could change how age-related diseases are prevented and treated. Prof Maudsley, quoted in the article, acknowledged that "much research remains to be done."